Briefing
MiRaDE: ctDNA minimal residual disease after prostatectomy for high-risk prostate cancer
Pilot cohort study of a prostate-specific ctDNA panel to estimate how often minimal residual disease is detected six weeks after radical prostatectomy and how that result relates to early distant relapse.
- Design: Not applicable · Recruiting